David Venables wins the Disruptor category of EY Entrepreneur Of The Year 2018, Scotland

Edinburgh, UK, 22nd June 2018 / Sciad Newswire / Synpromics, the leader in gene control, is delighted to announce that David Venables, CEO of the Company, has won the ‘Disruptor’ category of Scotland’s EY Entrepreneur Of The Year 2018. 

David was nominated in the ‘Disruptor’ category, recognising entrepreneurs ‘with the vision and courage to challenge the status quo’ and for ‘shaping and improving our working world and constantly striving for excellence’. The judges commented “David won the disruptor category for his clever business model. With David’s vision and great strategy, the company has raised in excess of £7m since 2015, moved to new facilities to accommodate the growing number of staff, and opened operations in the U.S.”

Receiving the award, David Venables commented: “I am thrilled to receive such a prestigious award, especially when up against so many fantastic entrepreneurs contributing so much to the Scottish economy. Synpromics continues to grow and thrive, revolutionising gene control and promoter design, and I am delighted to be leading our dedicated team to furthering this goal.”

Synpromics’ technology enables unprecedented control of gene expression through its ability to custom design synthetic cell-type, or condition, specific promoters. David’s dependable leadership of the Company over the past four years has uniquely facilitated the Company’s expansion, and rightly merits this esteemed award. 

EY Entrepreneur Of The Year recognises the contribution of entrepreneurs to the UK economy and this year celebrates its 20th anniversary. 

Ends

For further information, contact:

Corporate Contact:
David Venables, Chief Executive Officer
Synpromics Ltd
T: +44 (0)131 651 9662
E: david.venables@synpromics.com

PR Contact:

Deborah Cockerill / Juliette Craggs
Sciad Communications Ltd
T: +44 (0)20 7470 8801
E: synpromics@sciad.com

Notes to Editors

About Synpromics 
Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design. The Company has developed PromPT^®, its multi-dimensional bioinformatics database that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications. The company operates in a diverse range of fields, including broad applications in cell and gene based medicine, biologics manufacturing and viral vector bioprocessing. Current partners include Audentes, Biomarin, uniQure, AGTC, Solid Biosciences, Homology Medicines Inc, Adverum Biotechnologies, GE Healthcare and Sartorius-Stedim Cellca, as well as numerous undisclosed partners in the pharmaceutical sector.

About synthetic promoters
Naturally occurring promoters have evolved for biological functions but have limitations when utilised in industrial or therapeutic applications. Synthetic promoters with DNA sequences not found in nature are designed to better regulate gene activity and precisely control protein production. Synpromics creates highly specific promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. Each synthetic promoter represents a novel invention and thus can be patented.

For more information visit www.synpromics.com 

Photo Courtesy of EY: (from left to right) Jeremy Vine, David Venables and Mike Timmins